An overview of PROTACs: a promising drug discovery paradigm
Z Liu, M Hu, Y Yang, C Du, H Zhou, C Liu, Y Chen… - Molecular …, 2022 - Springer
Proteolysis targeting chimeras (PROTACs) technology has emerged as a novel therapeutic
paradigm in recent years. PROTACs are heterobifunctional molecules that degrade target …
paradigm in recent years. PROTACs are heterobifunctional molecules that degrade target …
Induced protein degradation for therapeutics: past, present, and future
The concept of induced protein degradation by small molecules has emerged as a
promising therapeutic strategy that is particularly effective in targeting proteins previously …
promising therapeutic strategy that is particularly effective in targeting proteins previously …
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive
characterization of T cell diversity may be key to understanding the success of …
characterization of T cell diversity may be key to understanding the success of …
IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact
S Bird, C Pawlyn - Blood, The Journal of the American Society …, 2023 - ashpublications.org
Immunomodulatory agents (IMiDs) are a cornerstone of treatment for patients with multiple
myeloma. IMiDs are used in therapeutic combinations at all stages of disease and are …
myeloma. IMiDs are used in therapeutic combinations at all stages of disease and are …
Encapsulation of nano‐bortezomib in apoptotic stem cell‐derived vesicles for the treatment of multiple myeloma
Z Cao, P Li, Y Li, M Zhang, M Hao, W Li, X Mao, L Mo… - Small, 2023 - Wiley Online Library
Extracellular vesicles (EVs) are lipid bilayer nanovesicles released from living or apoptotic
cells that can transport DNA, RNA, protein, and lipid cargo. EVs play critical roles in cell–cell …
cells that can transport DNA, RNA, protein, and lipid cargo. EVs play critical roles in cell–cell …
Genome instability in multiple myeloma: Facts and factors
Simple Summary Multiple myeloma is an incurable blood cancer caused by the malignant
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …
Targeting cereblon in hematologic malignancies
O Fuchs - Blood Reviews, 2023 - Elsevier
The protein cereblon (CRBN) is a substrate receptor of the cullin 4-really interesting new
gene (RING) E3 ubiquitin ligase complex CRL4 CRBN. Targeting CRBN mediates selective …
gene (RING) E3 ubiquitin ligase complex CRL4 CRBN. Targeting CRBN mediates selective …
Addressing genetic tumor heterogeneity, post-therapy metastatic spread, cancer repopulation, and development of acquired tumor cell resistance
Simple Summary The present review summarizes and interprets uniform therapy schemes
for rescuing relapsed or refractory (r/r) neoplasias of quite different histologic origins …
for rescuing relapsed or refractory (r/r) neoplasias of quite different histologic origins …
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
The acquisition of a multidrug refractory state is a major cause of mortality in myeloma.
Myeloma drugs that target the cereblon (CRBN) protein include widely used …
Myeloma drugs that target the cereblon (CRBN) protein include widely used …
Single-nucleotide variants and epimutations induce proteasome inhibitor resistance in multiple myeloma
Purpose: Proteasome inhibitors (PI) are the backbone of various treatment regimens in
multiple myeloma. We recently described the first in-patient point mutations affecting the 20S …
multiple myeloma. We recently described the first in-patient point mutations affecting the 20S …